ECOR electroCore

electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025

electroCore to Announce First Quarter March 31, 2025 Financial Results on Wednesday, May 7, 2025

ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025.

Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below:

Wednesday, May 7, 4:30 PM EST

Dial-In: (646) 931-3860

Webinar ID: 885 4355 1292

Passcode: 419231

Registration Link: to participate and ask questions on the call.

About electroCore, Inc.

electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies.

For more information, visit .

Contact

ECOR Investor Relations

(973) 302-9253



EN
30/04/2025

Underlying

ECORelectroCore

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on electroCore

 PRESS RELEASE
Free
ECOR ELECTROCORE

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctiv...

gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). “The CDC reports approximately 2.5 mil...

September 30, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/I...

electroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clin...

September 29, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(...

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4) ROCKAWAY, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Andy Brown has joined electroCore, effective September 9, 2025, as the Company’s VP, Corporate Controller. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Mr. Brown in connection with the commencement of his employment. The RSUs were granted as an inducement material...

September 10, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Announces Departure of Peter Cuneo from the Board of Direc...

electroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board ROCKAWAY, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the departure of Peter Cuneo from the Board of Directors and that Thomas J. Errico, MD, has been elected to succeed Mr. Cuneo as Chairman of the Board, effective September 2, 2025. Mr. Cuneo will continue as a strategic advisor to the Company. “I want to offer my gratitude, and my congratulations...

September 5, 2025 1 EN
 PRESS RELEASE
Free
ECOR ELECTROCORE

electroCore Partners with iHeartRadio and Former New York Jets Star Li...

electroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief ROCKAWAY, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its partnership with Greg Buttle, former New York Jets linebacker and NFL star, to help raise awareness of Truvaga™ Plus, the Company’s next-generation handheld vagus nerve stimulation (nVNS) device designed to promote calm, clarity, and better sleep. As a standout NFL player and respected spor...

September 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch